Similar to the DLD‐1 cell system, we removed endogenous ADAM17 using CRISPR/Cas9 from the mouse breast cancer cell line 4T1 and exogenously expressed the different ADAM17 variants (Figs 6D, and EV4I and J). This evidence concerns the gene ADAM17 and breast carcinoma.